@jodiemburton @NightShiftMD @BrianAlperMD @BMJ_EBM @MedFactChecks @ravigarg415 You claim “there is absolutely no debate” I’ve provided 1 peer-reviewed publication that doesn’t support your position. The 1 masked RCT <3hrs claiming efficacy for primary
@AJWPharm @davehartin Not sure there’s a perfect study. Only NINDS-2 & ECASS-3 claimed superiority for primary outcome in different time windows. Not replicated. Re-analyses questions findings. https://t.co/S5Twf89m4R https://t.co/HpzhP1BK2q
@drjohnm @BrianAlperMD @BMJ_EBM Here's analysis of NINDS data by neurologist @ravigarg415 showing high risk of selection bias. "Treatment decisions and guideline recommendations based on the original treatment effect reported in the NINDS rt-PA Stroke St
@AJWPharm Are you familiar with the Neurologist @ravigarg415 work on NINDS and the concerns about the fidelity of the randomization. Randomization is a key aspect to RCTs. Lack of randomization can bias the results. https://t.co/vLtdAxA00W #EBM